Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 3 , Pages 240-248 , March 2009

Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical Pearls

,Accepted 23 November 2008.

References 

  1. Beiderman J , Spencer TJ . Psychopharmacological interventions . Child Adolesc Psychiatric Clin N Am . 2008;17:439–458
  2. American Academy of Pediatrics Committee on Quality Improvement and Subcommittee on Attention-Deficit/Hyperactivity Disorder  . Treatment of attention deficit/hyperactivity disorder: overview of the evidence . Pediatrics . 2005;115:e749–e757
  3. Pliskz S . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry . 2007;46:894–921
  4. Faraone SP , Biederman J , Morley Christopher P , et al.   Effect of stimulants on height and weight: a review of the literature . J Am Acad Child Adolesc Psychiatry . 2008;47:994–1009
  5. Hinshaw SP . Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work . J Pediatr Psychol . 2007;32:664–675
  6. Towbin K . Paying attention to stimulants: height, weight, and cardiovascular monitoring in clinical practice . J Am Acad Child Adolesc Psychiatry . 2008;47:977–980
  7. In: Red Book: Pharmacy's Fundamental Reference . 2008 ed.. Montvale, NJ: Thomson Healthcare; 2008;p. 203–804
  8. Faraone SV, Spencer TJ, Aleadri M et al. Comparing the Efficacy of Medications Used for ADHD Using Meta-Analysis. Paper Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco: May 2003.
  9. Pelham WE , Greenslade KE , Vodde-Hamilton M , et al.   Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline . Pediatrics . 1990;86:226–237

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials, and includes discussions that are “off-label” from the perspective of the U.S. Food and Drug Administration. Although we fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care, this column focuses primarily on psychopharmacological management. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

PII: S0890-8567(09)60023-X

doi: 10.1097/CHI.0b013e318197748f

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 3 , Pages 240-248 , March 2009

Article Tools

* Image Usage & Resolution